FindTrial
Sign In

Assessment of Risk of Depression, Anxiety, and Stress among Type-2 Diabetic Patients on Oral Antidiabetics.

Assessment of Risk of Depression, Anxiety, and Stress among Type-2 Diabetic Patients on Oral Antidiabetic Agents : A Cross-sectional Study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/10/059060
Enrollment
225
Registered
2023-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Control Intervention1: Nil: Nil

Sponsors

Justice K S Hegde Charitable Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects on metformin+sulphonylureas/SGLT2I+other OHAs/DPP4I+other OHAs for at least 30 days prior to enrolment in the study 2. Participants who are willing to give consent.

Exclusion criteria

Exclusion criteria: 1. T2DM patients with life-threatening complications 2. Pregnant women 3. Patients taking SGLT2I, DPP4I in combination. 4. Patients who are severely disabled, deaf, or mute 5. Patients taking antidepressants 6. Patients with: (i)Neurological or severe psychiatric disease (ii)Depression or anxiety with onset prior to starting OHAs.

Design outcomes

Primary

MeasureTime frame
Depression Timepoint: At baseline visit—

Secondary

MeasureTime frame
FBS PPBS RBS HbA1C BP HDL LDL TGs TC Timepoint: At baseline visit—

Countries

India

Contacts

Public ContactRoopa Satyanarayan Basutkar

NGSM Institute of Pharmaceutical Sciences

roopa.satyanarayan@nitte.edu.in9047155003

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026